Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
Koblan
K S
KS
Department of Cancer Research, Merck Research Laboratories, West Point, PA 19486, USA.
Kohl
N E
NE
Omer
C A
CA
Anthony
N J
NJ
Conner
M W
MW
deSolms
S J
SJ
Williams
T M
TM
Graham
S L
SL
Hartman
G D
GD
Oliff
A
A
Gibbs
J B
JB
D019883:Alkyl and Aryl Transferases; D000595:Amino Acid Sequence; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D051231:Farnesyltranstransferase; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology; D011487:Protein Conformation; D014166:Transferases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D018631:ras Proteins / Q000737:chemistry / Q000378:metabolism
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009842:Oligopeptides; C094719:cysteinyl-valyl-tryptophyl-methionine; D014166:Transferases; D019883:Alkyl and Aryl Transferases; C083291:geranylgeranyltransferase type-I; C064911:p21(ras) farnesyl-protein transferase; D051231:Farnesyltranstransferase; D018631:ras Proteins